Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening
about
CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, and Steps to Autoimmunity: A Unifying HypothesisEpstein-Barr virus latent genesPrediction of inhibitory activity of epidermal growth factor receptor inhibitors using grid search-projection pursuit regression methodLigand pose and orientational sampling in molecular dockingAssay Development and High-Throughput Screening for Inhibitors of Kaposi's Sarcoma-Associated Herpesvirus N-Terminal Latency-Associated Nuclear Antigen Binding to Nucleosomes.Epstein-Barr virus and multiple sclerosis: potential opportunities for immunotherapyRoscovitine inhibits EBNA1 serine 393 phosphorylation, nuclear localization, transcription, and episome maintenancePharmacophore-based virtual screening and biological evaluation of small molecule inhibitors for protein arginine methylationUnbiased mutagenesis of MHV68 LANA reveals a DNA-binding domain required for LANA function in vitro and in vivo.Binding modes of peptidomimetics designed to inhibit STAT3.Sulfated small molecules targeting eBV in Burkitt lymphoma: from in silico screening to the evidence of in vitro effect on viral episomal DNA.Mice with human immune system components as in vivo models for infections with human pathogens.The essential role of Epstein-Barr virus in the pathogenesis of multiple sclerosisDevelopment of drugs for Epstein-Barr virus using high-throughput in silico virtual screeningSmall molecule inhibition of Epstein-Barr virus nuclear antigen-1 DNA binding activity interferes with replication and persistence of the viral genome.Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes.Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patientsDesign and development of antivirals and intervention strategies against human herpesviruses using high-throughput approach.Epstein-Barr virus and Burkitt lymphoma.DNA ligand designed to antagonize EBNA1 represses Epstein-Barr virus-induced immortalization.Zinc finger E-box binding factor 1 plays a central role in regulating Epstein-Barr virus (EBV) latent-lytic switch and acts as a therapeutic target in EBV-associated gastric cancer.Computational analysis of EBNA1 "druggability" suggests novel insights for Epstein-Barr virus inhibitor design.Structural and Functional Basis for an EBNA1 Hexameric Ring in Epstein-Barr Virus Episome Maintenance.Antimicrobial sulfonamides clear latent Kaposi sarcoma herpesvirus infection and impair MDM2-p53 complex formation.EBNA1-specific luminescent small molecules for the imaging and inhibition of latent EBV-infected tumor cells.Exploration of potential EGFR inhibitors: a combination of pharmacophore-based virtual screening, atom-based 3D-QSAR and molecular docking analysis.Clinical Importance of Epstein⁻Barr Virus-Associated Gastric Cancer.
P2860
Q21296711-3B47D5DD-362B-4040-B18B-E45BAE994D96Q28082701-BCCB8304-DE8A-49B1-9B2F-E45F0564C4A3Q28479238-E626C734-DEC1-45A8-8932-7BC33324B397Q28533958-9D20A62A-D9AA-4539-BC7F-D1B7225DCF3DQ30398275-01B68035-B190-4D28-9B5B-9E3588EEC2A9Q30878158-25E2F33B-49AF-4DD3-A640-5602DDB61F47Q33786506-D5821C16-7D3C-43E2-8F52-D9190ABD9B2CQ34113450-61144D25-7444-4E3D-9F35-E5288D12D028Q34411851-632A85D9-BAC6-4F16-AD7F-65B5F6096AA0Q34516992-6296E8A8-FC41-4954-8455-2C365DA37DB7Q34563797-61FED29B-98D9-47B3-98FF-C30C4E0C8F85Q34920166-7D643F48-2E2B-42E7-8B1F-173752A5A964Q37151141-AFB53D4E-5DA6-4C23-A44C-739AC3C8BFC4Q37278489-B1810CD3-8B1D-4EAE-AA16-3856419BFA87Q37660246-62D4B10F-23DD-4588-A4DA-C062C7A2E20CQ37849461-59592985-D698-46D3-87EA-A8433C0C86BEQ37865141-C752368A-4E81-49AF-BD77-B30A6C19F40BQ38227257-A2A8E8D5-7F0F-4D85-BAE3-DD3437B6DC45Q38270680-4C65CF0A-3F30-4E9A-AB17-33599D5B0FEEQ39475483-006503E3-A61A-4CD3-BB21-85FE882110ADQ39515516-BA3A08DA-EE8E-4621-943A-071EBFBBC5F5Q39743323-384F2E0D-3841-4000-8CF7-3997DCB9E168Q40125313-05EF0948-4B04-4E01-90A5-874347497D7BQ40161262-3E7AB076-74A8-4865-A3E8-575D9C01BD1DQ42219143-715A940A-0789-4F44-AA86-36DAE8333F1DQ51063758-03BA5075-0D34-4C45-9525-0CC431F20619Q55515323-EA97B519-D9C4-428E-B638-4B555245765D
P2860
Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Discovery of selective inhibit ...... ut in silico virtual screening
@ast
Discovery of selective inhibit ...... ut in silico virtual screening
@en
Discovery of selective inhibit ...... ut in silico virtual screening
@nl
type
label
Discovery of selective inhibit ...... ut in silico virtual screening
@ast
Discovery of selective inhibit ...... ut in silico virtual screening
@en
Discovery of selective inhibit ...... ut in silico virtual screening
@nl
prefLabel
Discovery of selective inhibit ...... ut in silico virtual screening
@ast
Discovery of selective inhibit ...... ut in silico virtual screening
@en
Discovery of selective inhibit ...... ut in silico virtual screening
@nl
P2093
P2860
P1433
P1476
Discovery of selective inhibit ...... ut in silico virtual screening
@en
P2093
David C Schultz
Hualiang Jiang
Paul M Lieberman
Scott Thompson
Weiliang Zhu
P2860
P304
P356
10.1371/JOURNAL.PONE.0010126
P407
P577
2010-04-12T00:00:00Z